Cited by 188Pain Mechanisms and TreatmentsPain Management and TreatmentMusculoskeletal pain and rehabilitation

Neuropathic pain in the community: more under-treated than refractory?

Open access
Torrance, Nicola, Ferguson, Janice A., Afolabi, Ebenezer, Bennett, Michael I., Serpell, Michael G., Dunn, Kate M., Smith, Blair H.·2013·Pain

Abstract

Best current estimates of neuropathic pain prevalence come from studies using screening tools detecting pain with probable neuropathic features; the proportion experiencing significant, long-term neuropathic pain, and the proportion not responding to standard treatment are unknown. These "refractory" cases are the most clinically important to detect, being the most severe, requiring specialist treatment. The aim of this study was to estimate the proportion of neuropathic pain in the population that is "refractory," and to quantify associated clinical and demographic features. We posted self-administered questionnaires to 10,000 adult patients randomly selected from 10 general practitioner practices in 5 UK locations. The questionnaire contained chronic pain identification and severity questions, cause of pain, SF-12, EQ-5D, S-LANSS (Self-administered Leeds Assessment of Neuropathic Signs and Symptoms), PSEQ (Pain Self-Efficacy Questionnaire), use of neuropathic pain medications, and health care utilisation. These data were combined to determine the presence and characteristics of "refractory" neuropathic pain according to the defining features identified by a Delphi survey of international experts. Graded categories of chronic pain with and without neuropathic characteristics were generated, incorporating the refractory criteria. Completed questionnaires were returned by 4451 individuals (response rate 47%); 399 had "chronic pain with neuropathic characteristics" (S-LANSS positive, 8.9% of the study sample); 215 (53.9%) also reported a positive relevant history ("Possible neuropathic pain"); and 98 (4.5% of all Chronic Pain) also reported an "adequate" trial of at least one neuropathic pain drug ("Treated possible neuropathic pain"). The most refractory cases were associated with dramatically poorer physical and mental health, lower pain self-efficacy, higher pain intensity and pain-related disability, and greater health care service use.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.pain.2012.12.022

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [8]British National Formulary BMA 2010 BMJ Group and Pharmaceutical Press Royal Pharmaceutical Society, London

Cited by

Sorted by citations

Authors
Torrance, N., Ferguson, J. A., Afolabi, E., Bennett, M. I., Serpell, M. G., Dunn, K. M., & Smith, B. H.
Affiliations
  • University of Leeds (GB)
  • University of Dundee (GB)
  • University of Aberdeen (GB)
  • University of Glasgow (GB)
  • Keele University (GB)
Corresponding author
Torrance, Nicola
Venue
Pain
Published
2013-05
Volume
154
Issue
5
Pages
690-699
ISSN
0304-3959 (ISSN-L)
OpenAlex
W2026664444
Cited by
188
References
48
Citations by year
2026: 8 · 2025: 14 · 2024: 12 · 2023: 9 · 2022: 7 · 2021: 20 · 2020: 19 · 2019: 13 · 2018: 19 · 2017: 22 · 2016: 12 · 2015: 12 · 2014: 9 · 2013: 12
FWCI
10.42
Type
journal article
Language
en
Open access
Locations
  • Pain (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Discovery Research Portal (University of Dundee) (submittedVersion)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
Funders
Pfizer UK Ltd. Kate Dunn is supported by the Wellcome Trust (083572)
Topics
  • Health Sciences › Medicine › Physiology › Pain Mechanisms and Treatments
  • Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Treatment
  • Health Sciences › Medicine › Pharmacology › Musculoskeletal pain and rehabilitation
Keywords
neuropathic pain, refractory neuropathic pain, undertreatment, prevalence, chronic pain, pain self-efficacy, pain-related disability, health care utilization, physical and mental health, neuropathic pain medications, community-dwelling adults, general practice
MeSH terms
Adolescent, Adult, Aged, Analgesics, Data Interpretation, Statistical, Drug Resistance, Humans, Male, Middle Aged, Neuralgia, Pain Measurement, Quality of Life, Surveys and Questionnaires, Socioeconomic Factors, Prevalence, Treatment Outcome, Self Efficacy, Young Adult, Chronic Pain

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review